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Abstract
The first total synthesis of the naturally occurring tetracyclic homoisoflavonoid brazilein (1) and 14
new analogs (1a–n) is reported. Target compounds and intermediates were assayed for anti-
inflammatory effects on superoxide anion generation and elastase release by human neutrophils in
response to fMLP/CB, and for cytotoxic activity against nasopharyngeal (KB), vincristine-resistant
nasopharyngeal (KBvin), lung (A549) and prostate (DU-145) human cancer cell lines. The most
active compound 1b showed potent effects on superoxide anion generation and elastase release with
IC50 values of 1.2 and 1.9 µM, respectively, and was 65 times more potent than phenylmethylsulfonyl
fluoride (PMSF), the positive control, in the latter assay. Additionally, 1b exhibited broad spectrum
in vitro anticancer activity with IC50 values of 6–11 µM against the four tested cancer cell lines.
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Naturally occurring homoisoflavonoids (3-benzylidene-4-chromanones) are related
structurally to flavonoids, and exhibit various biological activities.1 Synthesis of the 3-
benzylidene-4-chromanone skeleton is usually based on the condensation of 4-chromanones
with aromatic aldehydes in the presence of an acidic or basic catalyst.2,3 Although members
of this family have been the subjects of several syntheses,4,5 there are no reports on the total
synthesis of brazilein (1) nor the preparation of 1-analogs.
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In our prior study, we isolated the unique tetracyclic homoisoflavonoid brazilein (1), whose
stereochemistry was obtained as dextrorotatory,6 from an ethyl acetate extract of Caesalpinia
sappan L. (Legminosae). Brazilein ((6aR)-6a,7-dihydro-3,6a,10-trihydro-benz[b]indeno[1,2-
d] pyran-9-(6H)-one) is a natural red pigment used in traditional Chinese medicine. It also
exhibits significant cytotoxic activity against HepG2 and Hep3B (liver), MDA-MB-231 and
MCF-7 (breast), A549 (lung) and Ca9-22 (gingival) human cancer cell lines (Table 1).6b
Previous literatures showed that brazilein (1) exhibited immunosuppressive activity in mice
lymphocytes,7 cardiotonic effects in isolated rat hearts,8 and anti-oxidant properties.9,10
Brazilin (2) is the hydrogenation product of brazilein (1) in the proposed biosynthetic route,
11 and can be oxidized to brazilein (1) when the extract has been exposed to air and light.
Beyond this redox chemistry, our interest in devising a general synthesis for this skeleton was
based on literature reports that brazilin (2) has cytotoxicity (Table 1)6 and anti-inflammatory
properties,12,13 acts as a micromolar telomerase inhibitor,14 and produces DNA nicks.15 These
properties are often associated with useful anticancer agents. Additionally, to the best of our
knowledge, brazilein (1) and its derivatives have not been studied for anti-inflammatory and
cytotoxic effects. Considering the structural similarities between brazilin (2) and brazilein
(1), we wanted to determine whether the latter exhibits a similar spectrum of in vitro anti-
inflammatory and anticancer effects.
We report herein a strategy that enables the preparation of 1 by construction of the benzylidene
moiety via acid- or base-catalyzed aldol condensation with aryl aldehydes. All newly
synthesized compounds, including structurally related intermediates, were assayed for in
vitro cytotoxicity against four human cancer cell lines, [KB (nasopharngeal), KBvin
(multidrug-resistant nasopharngeal over-expressing P-gp), A549 (lung) and DU-145
(prostate)] and for anti-inflammatory action in terms of superoxide anion generation and
elastase release by human neutrophils in response to fMLP/CB.
The general synthesis of brazilein (1) was achieved through the route outlined in Scheme 1. 7-
Hydroxy-4-chromanone (5), a key intermediate, was readily obtained by reaction of resorcinol
(3) and 3-chloropropionic acid promoted by trifluoromethanesulfonic acid to give 2’,4’-
dihydroxy-3-chloropropiophenone (4), which was further cyclized using 2M NaOH16 to give
5 in 78% yield. Treatment of 5 with iodomethane in the presence of K2CO3/acetone gave 6
(60%). Acid catalyzed17 condensation of 6 with 3,4-dimethoxybenzaldehyde afforded 7 (78%).
Epoxidation of 7 with alkaline hydrogen peroxide gave epoxy ketone 8 (90%), which was
reduced to the diol 9 (89%) with LiAlH4.3 Cyclization to the desired product was affected by
HClO4 3 to yield trimethylbrazilin 10 in 31% yield. Compound 10 was demethylated using
pyridine hydrochloride18 to give 2 in 36% yield. Brazilin (2) was oxidized with a catalytic
amount of iodine solution to give brazilein (1) in 78% yield.
In addition, the brazilein derivatives 1a, 1b/c, and 1d were obtained by esterification of 1 with
acetic anhydride, propionyl chloride, and benzoic chloride, respectively, in pyridine. For 1e
and 1f, 1 was reacted in strong base (NaH) with dimethylcarbamyl chloride and
diethylcarbamyl chloride to produce the desired products 1d and 1f, respectively. Compounds
1g–n were synthesized by the general Williamson method as described in previous reports.
19,20 Specifically, 1g–n were prepared by alkylation of 1 with iodomethane (1g and h),
iodoethane (1i and j), benzyl bromide (1k), allylbromide (1l and m) and prenyl bromide (1n),
in the presence of K2CO3 in acetone. Accordingly, the first total syntheses of 1 and 14 analogs
(1a–n) (Figure 1) were accomplished.
Anti-inflammatory activity
Synthesized 1, 2, and intermediates 7–10 together with analogs 1a–n, which are divided into
three classes based on the substitution pattern at C-3, C-6a and C-10 and functionalized into
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ester, carbamate and ether, were evaluated for anti-inflammatory action based on effects against
superoxide anion generation and elastase release by human neutrophils in response to fMLP/
CB. The assays were performed using established protocols,21,22 which are widely used to
identify potential anti-inflammatory compounds. Table 2 lists the results for the test
compounds, as well as diphenyleneiodonium (DPI) and phenylmethylsulfonyl fluoride
(PMSF), included as positive controls for superoxide anion generation and elastase release,
respectively. Results are expressed as the mean ± S.E.M., and comparisons were made using
Student's t-test. A probability of 0.05 or less was considered significant.
Among the esterified compounds 1a-d, analogs 1a (di-acetate) and 1d (tri-benzoate) showed
selective anti-inflammatory activity (1a vs superoxide anion generation, 18.7 µM; 1d vs
elastase release, 13.3 µM). Analog 1b (tri-proprionate) showed the highest potency against
both superoxide anion generation and elastase release with significant IC50 values of 1.2 and
1.9 µM, respectively. Analog 1c (di-propionate) was slightly less potent with IC50 values of
1.65 and 3.28 µM, but still was more active than the parent compound 1. Therefore, replacing
the hydroxy groups with propionate esters increased potency in both assays, particularly when
all three hydroxyls were esterified in 1b.
N-Diethyl carbamate 1f showed a weak effect (IC50 15.5 µM) in response to fMLP/CB-induced
elastase release, but neither 1f nor the N-dimethyl carbamate 1e showed a significant effect
against superoxide anion generation. Although the ester and carbamate functional group
present parallel physical and chemical properties, the data showed that the former did provide
better activity against either superoxide anion generation or elastase release.
Among the eight compounds (1g–n) containing ether substituents, 1g (tri-methoxy) and 1j (di-
ethoxy) displayed potent effects in the superoxide anion assay (IC50 4.7 and 4.4 µM,
respectively). Analog 1j (di-ethoxy) also showed a moderate effect (IC50 8.4 µM) against
elastase release, as did 1k (di-benzoxy) (IC50 8.8 µM). Compounds 1l-n (allyl and prenyl
ethers) were non-selective, but with only weak inhibitory effects in both assays (IC50 10–20
µM). These findings suggest that 1g and 1j merit further investigation as potential anti-
inflammatory compounds.
Furthermore, among the synthetic intermediates 7–10 (Table 1), the epoxy ketone 8 was
significantly potent and selective (IC50 1.9 µM) against superoxide anion generation. The diol
9 was moderately active in both anti-inflammatory assays (IC50 8.4 and 10.3 µM), while the
tetracyclic 10 was potent only against superoxide anion generation (IC50 4.5 µM).
In conclusion, among all screened compounds, including ester (1a–d), carbamate (1e and 1f),
and ether (1g–n) derivatives, the preliminary structure-activity relationship were addressed in
the order: a) ester > ether > carbamate; b) ethyl ≒ methyl > allyl ≒ prenyl > benzyl. In particular,
the most potent analog 1b was 65-fold more active than PMSF, the positive control, in the
elastase release assay.
Anti-cancer activity
The homoisoflavonoids 1a–n as well as the synthesized 1, 2 and intermediates 7–10 were
examined for in vitro cytotoxic activity against four human cancer lines. Table 3 lists the
IC50 values obtained with test compounds compared to the anticancer drug paclitaxel as a
positive control. Among the 14 derivatives (1a–n), seven compounds (1a–c, 1g, 1i, 1j and
1m) showed moderate potency against the tested human cancer cell lines with IC50 values of
5–18 µM; however, they all were much less active than paclitaxel.
In our previous study, the parent compound 1 showed moderate cytotoxic activity against six
cancer cell lines (IC50 8–34 µM, Table 1).6b Comparison of 1 to its synthetic intermediates 2
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and 7–10 showed that the epoxy ketone 8 had comparable or enhanced activity, while the
reduced diol 9 was inactive (IC50 >20 µM). In addition, trimethylbrazilin 10 was more active
than 2 with IC50 values of 10–15 µM against all four human cancer cell lines. The enhanced
cytotoxicity of epoxide analog 8 could account for its twofold greater potency than 1 against
superoxide anion generation.
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Molecular structures of brazilein (1), brazilin (2) and synthetic 1-analogs.
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Total synthesis of brazilein (1).
Reagents: (a) 3-Chloropropionic acid, CF3SO3H, 80 °C, 1h, 92%; (b) 2M NaOH, 0 °C, 2h,
78%; (c) Iodomethane, K2CO3, acetone, 60 °C, 5h, 60%; (d) 3,4-Dimethoxylbenzaldehyde,
EtOH, HCl gas, rt, overnight, 78%; (e) H2O2, dioxane, rt, 24h, 90%; (f) LiAlH4, THF, rt,
overnight, 89%; (g) HClO4, acetic acid, rt, overnight, 31%; (h) Pyridine-HCl, 190–200 °C, 3h,
36%; (i) 1N I2(aq), rt, overnight, 78%.
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Table 2
Inhibitory effects of compounds on superoxide anion generation and elastase release by human neutrophils in
response to FMLP/CB.
Compound
Superoxide anion Elastase release
IC50 (µM)a or (Inh %) IC50 (µM) a or (Inh %)
Brazilein (1) 4.0 ± 0.42 14. 2 ± 1.32
Brazilin (2) 4.6 ± 0.63 16.7 ± 0.41
1a 18.71 ± 2.82 (40.87 ± 3.49)***
1b 1.2 ± 0.02 1.9 ± 0.31
1c 1.65 ± 0.09 3.28 ± 0.51
1d (14.14 ± 5.70)* 13.25 ± 1.14
1e (16.37 ± 3.71) (11.39 ± 4.76)
1f (−7.00 ± 4.90) 15.50 ± 2.40
1g 4.65 ± 1.31 13.6 ± 1.09
1h (18.61 ± 6.29)* (26.76 ± 6.60)*
1i 23.94 ± 5.48 (35.54 ± 1.71)***
1j 4.35 ± 0.91 8.37 ± 0.41
1k (33.38 ± 7.75)** 8.76 ± 1.51
1l 16.16 ± 0.40 11.83 ± 2.00
1m 19.72 ± 4.44 16.54 ± 1.70
1n 19.69 ± 5.82 10.06 ± 0.60
7 NTb NTb
8 1.90 ± 0.32 (43.71 ± 2.00)***
9 8.38 ± 0.02 10.25 ± 0.14
10 4.52 ± 1.21 (35.76 ± 2.60)*
DPIc 0.7 ± 0.4
PMSFc 130.9 ± 2.91
a
IC50 represents the 50% inhibitory concentration of the compound. If 50% inhibition was not reached at any test dose, the percentage of inhibition




p < 0.01, and
***
p < 0.001 compared with the control value.
b
Abnormal absorption at OD405 and 550 nm.
c
DPI and PMSF were used as positive controls.
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Table 3
Cytotoxic effects of 1-analogs.
Compound Cancer Cell line (IC50 valuea, µM)
KB KBvin A549 DU-145
1a 10.0 ± 1.3 NDb 8.1 ± 1.2 8.2 ± 0.72
1b 6.6 ± 2.21 11.3 ± 1.53 13.5 ± 1.12 11.0 ± 0.47
1c 7.7 ± 3.5 NDb 7.8 ± 0.65 7.1 ± 0.44
1g 15.2 ± 1.41 16.9 ± 0.42 > 20 17.5 ± 0.67
1i 18.9 ± 1.11 17.9 ± 0.9 > 20 18.1 ± 1.54
1j 11.3 ± 0.78 16.5 ± 1.56 15.3 ± 1.04 11.0 ± 0.67
1m 5.4 ± 0.29 NDb 9.4 ± 0.49 9.1 ± 0.75
7 > 20 18.3 ± 0.26 > 20 > 20
8 9.8 ± 1.28 6.4 ± 0.67 > 20 10.6 ± 0.42
9 > 20 > 20 > 20 > 20
10 10.5 ± 0.48 7.6 ± 0.73 > 20 13.8 ± 1.26
Paclitaxelc 1.55×10−3 1.09×10−3 1.93×10−3 2.35×10−3
a
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